Engineered Immune Cells Fight Brain Metastases | Wake Forest Baptist
A new strategy offering hope in the fight against brain metastases, a particularly devastating complication of lung cancer, has emerged from research at Wake Forest University School of Medicine. Scientists have engineered immune cells – specifically, macrophages – to cross the blood-brain barrier and actively seek out and slow the growth of tumor cells in preclinical models. This development addresses a significant challenge in cancer treatment: the difficulty of delivering therapies to the brain due to its natural defense mechanisms.
Understanding Brain Metastases and the Blood-Brain Barrier
Brain metastases occur when cancer cells spread from their primary site – in this case, lung cancer – to the brain. Nearly one in three patients with lung cancer will experience this complication, making it a critical area of research. Current treatments like surgery and radiation therapy often have limited effectiveness because many drugs struggle to penetrate the blood-brain barrier, a highly selective membrane that protects the brain from harmful substances. This barrier, while essential for brain health, inadvertently hinders the delivery of potentially life-saving medications.
Macrophages are immune cells that naturally navigate into the brain. Researchers at Wake Forest, led by Shih‑Ying Wu, Ph.D., assistant professor of radiation oncology, capitalized on this inherent ability. Their approach involved engineering these macrophages to express a chimeric antigen receptor (CAR), creating what they term a CAR macrophage, or CARMA. This CAR acts like a guided missile, specifically targeting a protein called mesothelin, which is found in high concentrations on lung cancer cells that have metastasized to the brain. The findings were published online today in Nature Biomedical Engineering.
How CAR Macrophages Operate: A Deeper Dive
CARs are not naturally occurring; they are engineered receptors that combine the antigen-binding domain of an antibody with the signaling domain of a T cell receptor. This combination allows the CAR macrophage to recognize and bind to the mesothelin protein on cancer cells, triggering an immune response that destroys the tumor cells. The key innovation here is adapting this technology – typically used with T cells – to macrophages, leveraging their natural ability to cross the blood-brain barrier.
The study, as reported by News-Medical.net, demonstrated that these engineered macrophages successfully entered the brain, located cancer cells, and slowed tumor growth in preclinical models. It’s important to note that these are early-stage findings, conducted in laboratory settings and animal models. Further research is needed to determine the safety and efficacy of this approach in humans.
Atrium Health Wake Forest Baptist: A Center for Brain Tumor Care
The research was conducted at Atrium Health Wake Forest Baptist, a Comprehensive Cancer Center recognized for its multidisciplinary approach to brain tumor treatment. The center offers a range of advanced therapies, including Gamma Knife® stereotactic radiosurgery and laser ablation technology, and participates in clinical trials through the Adult Brain Tumor Consortium (ABTC), an NCI-sponsored group dedicated to advancing brain tumor research. This participation in the ABTC allows patients access to cutting-edge treatments and collaborative research efforts. The center emphasizes a patient-centered approach, providing dedicated coordinators to support patients throughout their care journey.
Limitations and Future Directions
While the results are promising, it’s crucial to acknowledge the limitations of preclinical studies. Animal models do not always accurately predict how a treatment will perform in humans. Factors such as the immune system, tumor microenvironment, and drug metabolism can differ significantly between species. The study focused specifically on lung cancer brain metastases targeting the mesothelin protein. It remains to be seen whether this approach will be effective for other types of brain metastases or cancers.
The next steps involve further refining the CAR macrophage technology and conducting rigorous safety and efficacy testing in preparation for potential clinical trials. Researchers will need to carefully evaluate the potential for off-target effects, where the CAR macrophages might attack healthy cells, and optimize the dosage and delivery method to maximize therapeutic benefit. The team will also investigate whether combining CAR macrophage therapy with other treatments, such as chemotherapy or radiation therapy, could enhance its effectiveness.
The Broader Context of Brain Metastasis Research
The development of CAR macrophages represents a significant advancement in the field of brain metastasis research. Traditionally, treating brain metastases has been challenging due to the blood-brain barrier and the aggressive nature of these tumors. Current treatment options often provide limited long-term benefit, and recurrence rates are high. This research offers a potential new avenue for delivering targeted therapies directly to the brain, potentially improving outcomes for patients with this devastating condition.
Ongoing research is also exploring other strategies to overcome the blood-brain barrier, such as using nanoparticles to encapsulate drugs and deliver them directly to tumor cells, and developing drugs that can temporarily disrupt the barrier to allow greater drug penetration. The ultimate goal is to develop a combination of therapies that can effectively control brain metastases and improve the quality of life for patients.
What comes next: Researchers at Wake Forest University School of Medicine are actively planning further preclinical studies to optimize the CAR macrophage therapy and assess its long-term effects. The team is also working to identify biomarkers that can predict which patients are most likely to benefit from this treatment, paving the way for personalized medicine approaches.